| __timestamp | Ascendis Pharma A/S | TG Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 24518692 |
| Thursday, January 1, 2015 | 9415000 | 19886580 |
| Friday, January 1, 2016 | 11504000 | 12631689 |
| Sunday, January 1, 2017 | 13482000 | 21977998 |
| Monday, January 1, 2018 | 25057000 | 20759000 |
| Tuesday, January 1, 2019 | 48473000 | 20838000 |
| Wednesday, January 1, 2020 | 76669000 | 121812000 |
| Friday, January 1, 2021 | 160180000 | 152137000 |
| Saturday, January 1, 2022 | 221227000 | 83231000 |
| Sunday, January 1, 2023 | 264410000 | 122706000 |
| Monday, January 1, 2024 | 284545000 |
Unveiling the hidden dimensions of data
In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Ascendis Pharma A/S and TG Therapeutics, Inc. have shown distinct trends in their SG&A expenses from 2014 to 2023. Ascendis Pharma A/S has seen a remarkable increase, with expenses growing by over 4,100% from 2014 to 2023. This surge reflects their aggressive expansion and investment in administrative capabilities. In contrast, TG Therapeutics, Inc. experienced a more modest growth of approximately 400% over the same period, indicating a more conservative approach to scaling operations. Notably, in 2021, both companies reached their peak SG&A expenses, with Ascendis Pharma A/S surpassing TG Therapeutics, Inc. by a significant margin. These trends highlight the strategic differences in managing operational costs within the biopharma sector.
Amgen Inc. or Ascendis Pharma A/S: Who Manages SG&A Costs Better?
Takeda Pharmaceutical Company Limited vs Ascendis Pharma A/S: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Alnylam Pharmaceuticals, Inc. or Ascendis Pharma A/S
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Veracyte, Inc.
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Soleno Therapeutics, Inc.
Ascendis Pharma A/S or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Ascendis Pharma A/S and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs TG Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing TG Therapeutics, Inc. and PTC Therapeutics, Inc.
Comparing SG&A Expenses: TG Therapeutics, Inc. vs Vericel Corporation Trends and Insights
Breaking Down SG&A Expenses: TG Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: TG Therapeutics, Inc. vs ImmunityBio, Inc. Trends and Insights